Table 3 Severity and outcomes of patients with COVID-19 categorized according to primary series dose of vaccine
|  | Primary series (− ) (n = 91) | Primary series ( +) (n = 29) | Booster doses (n = 93) | p-value |
|---|---|---|---|---|
Severity | ||||
 PaO2/FiO2 ratio | 141 (82–135) | 140 (105–234) | 139 (84–250) | 0.747 |
 SOFA | 8 (6–11) | 10 (5–12) | 8 (6–11) | 0.560 |
 APACHEII | 23 (19–28) | 24 (18–32) | 25 (17–29) | 0.883 |
 ARDS | 60 (64.5) | 21 (72.4) | 66 (71.0) | 0.563 |
Life support | ||||
 Mechanical ventilation | 53 (57.0) | 20 (69.0) | 58 (62.4) | 0.479 |
 Newly renal replacement therapy | 8 (8.6) | 2(6.9) | 11 (11.8) | 0.650 |
 ECMO | 2 (2.2) | 3 (10.3) | 3 (3.2) | 0.119 |
 Initial vasopressors use | 31 (33.3) | 8 (27.6) | 31 (33.3) | 0.828 |
Outcomes | ||||
 Hospital days | 30 (14–45) | 23 (13–43) | 25 (16–39) | 0.737 |
 28-day ventilator-free days | 0 (0–19) | 7 (0–16) | 10 (0–18) | 0.879 |
 In hospital mortality | 41 (44.1) | 11 (37.9) | 43 (46.2) | 0.734 |
 28-day mortality | 29 (31.2) | 7 (24.1) | 30 (32.3) | 0.704 |
 Time from symptoms onset to 1st Ct > 30, days | 11 (6–17) | 12 (6–18) | 9 (1–18) | 0.675 |